Description

JARDIANCE 10 MG

Indications

JARDIANCE (empagliflozin) 10 mg is primarily indicated for the management of type 2 diabetes mellitus in adults. It is used as an adjunct to diet and exercise to improve glycemic control. Additionally, JARDIANCE is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. The medication may also be prescribed for patients who have not achieved adequate glycemic control with other antidiabetic medications.

Mechanism of Action

JARDIANCE is classified as a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It works by inhibiting the SGLT2 protein in the proximal renal tubules, which decreases the reabsorption of glucose from the tubular fluid back into the bloodstream. This action leads to increased urinary glucose excretion, thereby lowering blood glucose levels. The reduction in glucose levels can also lead to weight loss and a decrease in blood pressure, contributing to its cardiovascular benefits.

Pharmacological Properties

The pharmacokinetics of JARDIANCE show that it is rapidly absorbed after oral administration, with peak plasma concentrations occurring within 1-2 hours. The bioavailability of empagliflozin is approximately 86%, and it is highly bound to plasma proteins (approximately 86%). The drug is metabolized primarily by the liver through glucuronidation and is excreted mainly in the urine. The half-life of empagliflozin is about 12 hours, allowing for once-daily dosing.

Contraindications

JARDIANCE is contraindicated in patients with a history of serious hypersensitivity reactions to empagliflozin or any of its components. It should not be used in patients with severe renal impairment (eGFR < 30 mL/min), end-stage renal disease, or those on dialysis. Additionally, it is not recommended for patients with a history of diabetic ketoacidosis (DKA).

Side Effects

Common side effects associated with JARDIANCE include urinary tract infections, genital mycotic infections, and increased urination. Other potential side effects may include dehydration, hypotension, and renal impairment. Serious adverse effects, although rare, may include acute kidney injury and serious allergic reactions. Patients should be monitored for signs of these side effects, particularly during the initiation of therapy.

Dosage and Administration

The recommended starting dose of JARDIANCE is 10 mg once daily, taken in the morning, with or without food. Based on individual glycemic control and tolerability, the dose may be increased to a maximum of 25 mg once daily. It is essential for patients to adhere to the prescribed dosage and consult their healthcare provider before making any changes to their medication regimen.

Interactions

JARDIANCE may interact with other medications, potentially affecting its efficacy or increasing the risk of adverse effects. Concomitant use of diuretics may increase the risk of dehydration and hypotension. Other medications that may affect renal function or glucose metabolism should be used cautiously in patients taking JARDIANCE. It is important for patients to inform their healthcare provider of all medications they are taking, including over-the-counter drugs and supplements.

Precautions

Before starting JARDIANCE, healthcare providers should assess the patient’s renal function, as the drug is contraindicated in those with severe renal impairment. Caution is advised in patients with a history of urinary tract infections or those prone to dehydration. Regular monitoring of renal function and electrolytes is recommended during treatment. Patients should be educated on the signs and symptoms of DKA and urinary tract infections, and they should be advised to seek medical attention if these occur.

Clinical Studies

Clinical studies have demonstrated the efficacy and safety of JARDIANCE in managing type 2 diabetes. In the EMPA-REG OUTCOME trial, JARDIANCE was shown to significantly reduce the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease compared to placebo. Other studies have highlighted its effects on weight loss and blood pressure reduction. The overall safety profile has been consistent across various studies, with the most common side effects being manageable and not leading to discontinuation of therapy in most patients.

Conclusion

JARDIANCE 10 mg is an effective treatment option for adults with type 2 diabetes, particularly those with cardiovascular risk factors. Its unique mechanism of action as an SGLT2 inhibitor provides additional benefits, including weight loss and cardiovascular protection. While generally well-tolerated, it is important for patients to be aware of potential side effects and interactions. Regular monitoring and communication with healthcare providers are essential to ensure safe and effective use of this medication.